Clinical Trial Detail

NCT ID NCT03834506
Title Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate adenocarcinoma

Therapies

Docetaxel + Prednisone

Dexamethasone + Docetaxel + Pembrolizumab + Prednisone

Age Groups: adult senior

No variant requirements are available.